Icon Plc (NASDAQ:ICLR) Given Consensus Rating of “Hold” by Analysts

Shares of Icon Plc (NASDAQ:ICLR) have been given an average recommendation of “Hold” by the seventeen analysts that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $148.80.

A number of research firms have weighed in on ICLR. Citigroup lowered their target price on Icon from $200.00 to $120.00 and set a “neutral” rating on the stock in a report on Wednesday, March 11th. TD Cowen raised shares of Icon from a “hold” rating to a “buy” rating and reduced their price target for the company from $183.00 to $120.00 in a research report on Wednesday, February 18th. Mizuho set a $216.00 price objective on shares of Icon in a research note on Friday, January 9th. Truist Financial reissued a “hold” rating and issued a $222.00 price objective (down from $231.00) on shares of Icon in a report on Thursday, January 8th. Finally, BMO Capital Markets raised shares of Icon from a “market perform” rating to an “outperform” rating and upped their target price for the company from $100.00 to $130.00 in a report on Thursday, March 26th.

Hedge Funds Weigh In On Icon

Institutional investors have recently bought and sold shares of the stock. Private Trust Co. NA grew its holdings in Icon by 200.0% during the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 94 shares during the period. Toth Financial Advisory Corp bought a new position in shares of Icon in the fourth quarter worth about $27,000. EFG International AG purchased a new position in shares of Icon during the 4th quarter valued at about $27,000. Ameriflex Group Inc. purchased a new position in shares of Icon during the 3rd quarter valued at about $33,000. Finally, Abound Financial LLC bought a new position in shares of Icon during the 4th quarter valued at approximately $54,000. 95.61% of the stock is owned by institutional investors.

Icon Price Performance

Shares of ICLR opened at $114.19 on Friday. The firm has a fifty day simple moving average of $119.14 and a two-hundred day simple moving average of $158.12. The firm has a market cap of $9.22 billion, a PE ratio of 15.45, a P/E/G ratio of 2.89 and a beta of 1.28. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon has a 1-year low of $66.57 and a 1-year high of $211.00.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.